iCas9 HA-T2A-antiCD19scFv-CD28-CD3z−BEAM

Item Information
Catalog #Size/ConcentrationPrice
Specification
ProductOrderI
Shipping InformationThis product will ship in a box containing dry ice at a temperature of -80°C. Learn More
Catalog#: PM-CAR1010
Inquire
Contact us to order
1-866-339-0871
510-740-3625
info@promab.com
Images
iCas9 HA-T2A-antiCD19scFv-CD28-CD3z−BEAM
Ab showing expression of scFv.
Positive control measured with flow cytometry
Figure 2: Transduction efficiency of icasp9-HA-CD19scFv-CD28-CD3zeta-GGGGSFlag CAR-T cells and CD19-CAR-T cells.
Figure 2: Transduction efficiency of icasp9-HA-CD19scFv-CD28-CD3zeta-GGGGSFlag CAR-T cells and CD19-CAR-T cells.
Addition of chemical inducer of dimerization measured with flow cytometry
Figure 3: Addition of chemical inducer of dimerization (CID) AP1903 100 nM for 24 hours did induce CAR-T cell killing.
Figure 3: Addition of chemical inducer of dimerization (CID) AP1903 100 nM for 24 hours did induce CAR-T cell killing.
Product Overview
Description

The inducible caspase-9-CD19 CAR construct consists of FKBP12 gene with mutation F36 to V coding two 12 kDa FK506 binding proteins with HA tag at the end fused to truncated Caspase9 (135-416; lacking pro-domain), followed by T2A peptide and then CD19scFv-CD28- CD3zeta without signaling peptide and with BEAM. This construct can be used as a negative control for PM-CAR1006-1M (it expressed same length as icasp-CD19 without tags but is nonfunctional protein). In the presence of dimerization agent, AP20187 or AP1903, caspase-9 is activated inducing cell killing. Introduction of inducible caspase-9 can be used for increasing safety of CAR-T cells in the presence of dimerization agent

Please view FAQs here